GREY — Grey Matters Health Share News
0.000.00%
Last trade - 00:00- CA$3.95m
- CA$4.69m
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement
Brief: Algernon To Acquire Nobrainer Imaging Centers
Brief: Algernon Pharmaceuticals Receives Notice Of Allowance From European Patent Office For Repirinast For Kidney Disease
Brief: Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
Brief: Algernon Pharmaceuticals Announces Increase To Private Placement
Brief: Algernon Pharmaceuticals Announces Private Placement
Brief: Algernon Pharmaceuticals Announces Private Placement
Brief: Algernon Pharmaceuticals Engages Maxim Group To Explore Spin-Off Of Ifenprodil Phase 2 Chronic Cough Drug Development Program
Brief: Algernon Pharmaceuticals Receives Notice Of Allowance From The Japanese Patent Office For Repirinast And The Treatment Of CKD
Brief: Algernon Pharmaceuticals Announces Closing Of Rights Offering
Brief: Algernon Pharmaceuticals Announces Notice Of Allowance For Method Of Use U.S. Patent Application
Brief: Algernon Pharmaceuticals Announces Launch Of Rights Offering
Brief: Algernon Neuroscience Provides Update On Phase 1 Dmt Clinical Study, Drug Found Safe To Proceed To Next Phase
Brief: Algernon Pharmaceuticals Enters Into A Clinical Trial Agreement With Yale University For A Dmt Phase 2 Depression Study
Brief: Algernon Pharmaceuticals Files For Orphan Designation With FDA For Ifenprodil
Brief: Algernon Pharmaceuticals Receives Approval For Groundbreaking Phase 1 DMT Human Stroke Study